HASS Valuation

Is A450330 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A450330 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A450330's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A450330's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A450330?

Key metric: As A450330 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A450330. This is calculated by dividing A450330's market cap by their current earnings.
What is A450330's PE Ratio?
PE Ratio	36.6x
Earnings	₩1.69b
Market Cap	₩61.90b

A450330 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.7x
Enterprise Value/EBITDA	14.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A450330's PE Ratio compare to its peers?

The above table shows the PE ratio for A450330 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.6x
A142280 Green Cross Medical Science	68.6x	n/a	₩82.1b
A059210 Meta Biomed	5.5x	n/a	₩81.1b
A131030 OPTUS Pharmaceutical	8.6x	n/a	₩87.7b
A100700 Sewoon Medical	7.8x	n/a	₩111.9b
A450330 HASS	36.6x	n/a	₩61.9b

Price-To-Earnings vs Peers: A450330 is expensive based on its Price-To-Earnings Ratio (36.6x) compared to the peer average (22.6x).

Price to Earnings Ratio vs Industry

How does A450330's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A035610 Solborn	2.6x	n/a	US$67.90m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A450330 is expensive based on its Price-To-Earnings Ratio (36.6x) compared to the KR Medical Equipment industry average (12.2x).

Price to Earnings Ratio vs Fair Ratio

What is A450330's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A450330 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	36.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A450330's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Boditech Med

₩347.2b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩15,760.00

-2.1%

-12.9%

Vieworks

₩200.2b

Develops, manufactures, and sells imaging systems and solutions.

A100120

₩21,000.00

3.4%

-24.2%

Access Bio

₩188.3b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,570.00

2.0%

-37.1%